Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
Evaluation of a Behavioural Intervention Using App Technology in CF
Cystic Fibrosis (CF) is a lifelong condition which causes the lungs and digestive system to become clogged with thick, sticky mucus. This leads to recurrent chest infections and reduced nutrient absorption from food.
- Trial name
- EAT-CF (NCT03782909)
- Testing
- Behaviour change intervention
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Cystic Fibrosis
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
- Trial name
- NCT00079742
- Testing
- Nutropin AQ [somatropin (DNA origin) injection]
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Mucoviscidosis Involving the Lung
Implementation of a Non-invasive Version of the Imaging β-adrenergic-dependent Sweat Secretion Test
The goal of this study is to implement a non-invasive version of the sweat secretion test based in visualization of sweat glands following β-adrenergic stimulation of sweat.
- Trial name
- BUBBLE TEST (NCT03584841)
- Testing
- Iontophoresis sessions in forearm of subjects with pilocarpine
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis, Glucose Metabolism Disorders
One Year Glargine Treatment in CFRD Children and Adolescents
Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements
- Trial name
- NCT00483769
- Testing
- Glargine
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Cystic Fibrosis
Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis
OBJECTIVES: I. Assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the cystic fibrosis transmembrane conductance regulator gene, in patients with…
- Trial name
- NCT00004779
- Testing
- Ad5-CB-CFTR
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Cystic Fibrosis
Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health.
- Trial name
- NCT00934362
- Testing
- Lucinactant first
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
Personalized Theratyping Trial
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
- Trial name
- NCT03587961
- Testing
- Symdeko
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- George Solomon
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Cystic Fibrosis
Probiotics on Intestinal Inflammation in Cystic Fibrosis
Cystic fibrosis (CF) is a complex systemic disease that mainly involves the respiratory and gastrointestinal (GI) tracts. The polymicrobial community composition of respiratory and GI tracts is influenced by both genetic and…
- Trial name
- NCT01961661
- Testing
- Lactobacillus rhamnosus GG
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Federico II University
Kartagener Syndrome, Cystic Fibrosis
Rare Genetic Disorders of the Breathing Airways
Mucociliary clearance, in which mucus secretions are cleared from the breathing airways, is the primary defense mechanism for the lungs.
- Conditions
- Kartagener Syndrome, Cystic Fibrosis, Pseudohypoaldosteronism, Primary Ciliary Dyskinesia
- Trial name
- NCT00323167
- Where
- 9 sites in United States, Canada
- Volunteers
- 367 people
- Sponsor
- University of North Carolina, Chapel Hill
Emphysema, Alveolitis, Fibrosing
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes.
- Conditions
- Emphysema, Alveolitis, Fibrosing, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00129350
- Testing
- Pulmonary rehabilitation programme
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis
Representations of Transplantation in Patients and in Health Care Professionals
Main objective : This project aims to have a better understanding of the influence of representations of patients with mucoviscidosis, their assistants and their medical persons in the choice of patients to accept or not lung…
- Trial name
- NCT01285882
- Testing
- Representations
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Nantes University Hospital
Cystic Fibrosis
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
The purpose of this study is to evaluate the relative bioavailability of a VX-828 tablet formulation compared to a suspension and evaluate its safety and tolerability.
- Trial name
- NCT06861413
- Testing
- VX-828
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis in Children
Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis
Cystic Fibrosis is the most prevalent fatal genetic disease affecting Canadian children and it primarily characterized by a thickening of pulmonary secretions and impaired mucociliary clearance.
- Trial name
- PPC (NCT04835376)
- Testing
- Percussion Palm Cup: Safety and Usability of Newly Designed Products in Infants and Children with Cystic Fibrosis
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- West Park Healthcare Centre
Cystic Fibrosis
Serum Zn Status of Patients With Cystic Fibrosis at Diagnosis and One Year Later, Compared to a Healthy Control Group
Serum Zn status of patients with cystic fibrosis at diagnosis and one year later, compared to a healthy control group
- Trial name
- NCT00221559
- Testing
- Blood sampling for determination of serum Zn
- Where
- Belgium
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis
Growth Hormone Therapy for Wasting in Cystic Fibrosis
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life.
- Trial name
- NCT00803179
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Massachusetts, Worcester
Cystic Fibrosis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to…
- Trial name
- NCT05090904
- Testing
- Brensocatib
- Where
- 14 sites in United States
- Volunteers
- 29 people
- Sponsor
- Insmed Incorporated
Cystic Fibrosis
Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients
The aim of this study is to evaluate the efficacy of a long-term domiciliary exercise program using the Wii video game platform as a training modality in Cystic Fibrosis (CF) patients.
- Trial name
- NCT02552043
- Testing
- Nintendo Wii exercise program
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Universidad Autonoma de Madrid
Cystic Fibrosis
Reproducibility of Virtual Exercise Assessments Versus Face-to-face Exercise Testing in Adults With Cystic Fibrosis
RExA-CF is investing if results from exercise tests (the Chester Step Test and the One-Minute Sit-to-Stand test) completed face to face are comparable to results of the same tests completed via a virtual teleconferencing…
- Trial name
- RExA-CF (NCT06565832)
- Testing
- One-Minute Sit-to-Stand Test, Chester Step Test
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis, CFTR Gene Mutation
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor…
- Trial name
- LunairCF (NCT06747858)
- Testing
- ARCT-032
- Where
- 13 sites in United States
- Volunteers
- 33 people
- Sponsor
- Arcturus Therapeutics, Inc.